Skip to main content

Table 1 (abstract P98). Changes from baseline in the Migraine Functional Impact Questionnaire domain scores

From: 11th European Headache Federation Congress jointly with 31st Congress of the Italian Society for the Study of Headaches

 

Least squares mean changes (95% confidence interval)

p-values (Erenumab vs Placebo)

Erenumab 70 mg

Erenumab 140 mg

Placebo

Erenumab 70 mg

Erenumab 140 mg

Physical function

−13.7 (−15.5, −11.9)

−15.1 (−17.0, −13.3)

−9.4 (−11.3, −7.6)

<0.001

<0.001

Usual activities

−12.3 (−13.9, −10.6)

−13.4 (−15.1, −11.8)

−8.3 (−10.0, −6.6)

<0.001

<0.001

Social function

−13.2 (−14.9, −11.4)

−14.5 (−16.2, −12.8)

−9.5 (−11.3, −7.7)

0.003

<0.001

Emotional function

−16.4 (−18.4, −14.5)

−18.4 (−20.3, −16.5)

−11.2 (−13.1, −9.2)

<0.001

<0.001